- CA$9.02m
- CA$6.04m
- $26.61m
Brief: Innocan Pharma Announces Encouraging Results From A Safety Assessment Study Of LPT-CBD On Minipigs
Brief: Innocan Pharma Reports Third Quarter 2024 Financial Results
Brief: Innocan To Focus Development Resources On Advancing Its Lpt-Cbd, A Monthly Injectable Treatment For Chronic Pain In Both Animals And Humans
Brief: Innocan Pharma's Lpt-Cbd Shows Long-Term Success In Relieving Osteoarthritis Pain In Dogs
Brief: Innocan Pharma Submits Investigational New Animal Drug Application To FDA's Veterinary Center
Brief: Innocan Pharma Engages Pain Management Expert In Preparation For Upcoming FDA Meeting
Brief: Innocan Pharma Engages Pain Management Expert In Preparation For Upcoming FDA Meeting
Brief: Innocan Pharma Initiates FDA Approval Process For Liposome Injection Therapy For Chronic Pain
Brief: Innocan Pharma Announces Expert Team For Lpt Cbd Application To United States Food And Drug Administration
Brief: Innocan Pharma Announces Closing Of First Tranche Private Placement And Provides Corporate Update
Brief: Innocan Pharma Announces Promising Successful Results In Efficacy Trial Of Diabetic Foot Relief Treatment
Brief: Innocan Pharma Announces Private Placement Of Units At A 9% Prime Above Share Price
Brief: Innocan Pharma Reports Success In A Pre-Clinical Trial Of A Liposomal-Cbd Injection On A Paralyzed Goat
Brief: Innocan Pharma Reports Annual 2022 Results
Brief: Innocan Reports Novel Cannabinoid Delivery Platform Patent Application